Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
- UPDATE: TheraPb Reports 11.2-Month Median rPFS With 212Pb-ADVC001 October 23, 2026
GX-BP1: Targeting SOX2 to Prevent Resistance in mCRPC
/in Preclinical Research, PROTACs/by MaxGX-BP1, a bioPROTAC-based SOX2 degrader, selectively targets SOX2, an undruggable protein, for ubiquitin-proteasome elimination, overcoming limitations of prior inhibition strategies. In preclinical models, GX-BP1 monotherapy delivered approximately 70% tumor growth inhibition, while combinations with agents like carboplatin/paclitaxel achieved 87-96% inhibition and near-complete tumor suppression at optimal doses. Notably, GX-BP1 paired with osimertinib eradicated cancer stem […]
TLX597-Tx Shows Early Promise in a Phase 2 PSMA Trial for Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxTLX597-Tx (177Lu-DOTA-HYNIC-panPSMA) is emerging as a next-generation PSMA-targeted radioligand therapy designed to deliver radiation more precisely to prostate cancer cells while limiting exposure to healthy organs. New data from the OPTIMAL-PSMA trial suggest that the drug may achieve strong tumor uptake with relatively low dose to the salivary glands and kidneys, two of the main […]
Phase 2 ARTEMIS-003 Trial: HS-20093 for mCRPC
/in Clinical Trial, Metastatic, Phase 2/by MaxHS-20093 has received Breakthrough Therapy designation from China’s National Medical Products Administration for metastatic castration-resistant prostate cancer. The designation covers patients previously treated with novel endocrine therapy and taxane-based chemotherapy, a setting where later-line treatment options remain limited. HS-20093 is a B7-H3-targeted antibody-drug conjugate designed to bind tumor cells expressing B7-H3 and deliver a cytotoxic […]
B7-H3 Emerges as Prime Target for Prostate Cancer Across All Stages
/in Observational/by MaxA 2026 study published in Clinical Cancer Research has pinpointed B7-H3 as a standout therapeutic target for prostate cancer, offering hope against the disease’s toughest forms. The work analyzed tissue from prostate cancer patients across the full spectrum, from hormone-sensitive and castration-resistant to neuroendocrine and “double-negative” subtypes, revealing B7-H3’s consistent, broad expression. This uniformity stands […]
Phase 1 Study of BPX-601: A Controlled Immune Therapy for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxA new clinical trial has recently begun for a promising but complex type of cancer treatment called BPX-601, designed specifically for men dealing with advanced prostate cancer that has stopped responding to traditional therapies. This therapy is a form of CAR T-cell treatment, which means doctors take a patient’s own immune cells, reprogram them in […]
Drugging the Undruggable: Million-Fold Leap Targets Prostate Cancer’s Elusive Androgen Receptor
/in Preclinical Research/by MaxProstate cancer treatments have hit a wall with castration-resistant cases, where tumors keep growing despite hormone blockers targeting the androgen receptor’s stable parts. A new study from University of British Columbia and BC Cancer researchers published on Nature cracks that open by hitting the receptor’s “undruggable” intrinsically disordered transactivation domain (NTD/TAD), the flexible region that […]
Not All Patients Benefit Equally: New Score Refines Cabazitaxel Use
/in Retrospective studies/by MaxA new analysis reports the development of a simple clinical score that may help physicians better identify which men are most likely to benefit from treatment with cabazitaxel after disease progression on earlier therapies. The work, based on a post-hoc analysis of the CABASTY study and validated in two major phase-3 trials, suggests that survival […]
B7‑H3 Expression Shapes Prognosis Differently Across Prostate Cancer Stages
/in Observational/by MaxA new observational study of more than 8,000 prostate tumors shows that B7‑H3 (CD276) expression helps shape prognosis and could open new paths for targeted therapies. Researchers analyzed 8,157 prostate cancer samples with matched DNA and RNA data, stratifying them by tissue site, hormone‑sensitivity status, and self‑reported race, then examined how B7‑H3 levels related to […]